

U.S. NAT'L PHASE OF PCT/FR00/01566**New and Redlined Version of Amended Claims**

1. (Amended) An immunostimulant oligonucleotide, ~~characterized in that it comprises~~ comprising at least one nucleotide sequence having the following formula 5' TTN₁N₂TT 3', in ~~which wherein~~ T signifies thymine, and N₁ and N₂ ~~may are~~ each independently represent adenine, thymine, cytosine or guanine, and ~~in that it wherein the oligonucleotide lacks a~~ dinucleotide CG in which the cytosine C is not methylated.
2. (Amended) The oligonucleotide as claimed in claim 1, ~~characterized in that it comprises~~ comprising from 6 to 100 nucleotides.
3. (Amended) The oligonucleotide as claimed in claim 1, ~~characterized in that~~ wherein N₁ represents adenine and ~~in that~~ N₂ represents guanine.
4. (Amended) The oligonucleotide as claimed in ~~one of the preceding claims,~~ characterized in that claim 1, wherein the 5' TTN₁N₂TT 3' unit is repeated at least once.
5. (Amended) The oligonucleotide as claimed in ~~the preceding claim,~~ characterized in that claim 4, wherein the 5' TTN₁N₂TT 3' unit is repeated twice.
6. (Amended) The oligonucleotide as claimed in either of claims 4 ~~and or~~ 5, ~~characterized in that wherein~~ the repeated 5' TTN₁N₂TT 3' units are separated by a nucleotide N₃ which, ~~each time, may be~~ is identical or different from other N₃ nucleotides, and which ~~may represent is~~ A, C, T, or G.
7. (Amended) The oligonucleotide as claimed in ~~the preceding claim 6,~~ characterized in that wherein the 5'-most nucleotide N₃ separating the first two TTN₁N₂TT units read when the sequence is in the 5'→3' orientation represents is cytosine.
8. (Amended) The oligonucleotide as claimed ~~in one of the preceding claims~~ according to claim 1, ~~characterized in that it comprises~~ comprising the sequence 5' TTAGTTCTTAGTTN₃TTAGTT 3', ~~in which wherein~~ A represents adenine, T represents thymine,

2022-09-20 09:20:50

G represents guanine and C represents cytosine, and in which wherein N₃ may signify is A, T, C, or G.

9. (Amended) The oligonucleotide as ~~claimed in one of the preceding claims~~according to claim 1, characterized in that it is capable of ~~induces~~inducing human lymphocyte proliferation.
10. (Amended) The oligonucleotide as ~~claimed in one of the preceding claims~~according to claim 1, characterized in that it is capable of ~~induces~~inducing cytokine secretion.
11. (Amended) The oligonucleotide as claimed in the ~~preceding claim 10~~, characterized in that it is capable of ~~producing~~induces IL 10 secretion.
12. (Amended) The oligonucleotide as claimed in claim 10, characterized in ~~that it is capable of~~induces γ interferon secretion.
13. (Amended) The oligonucleotide as ~~claimed in one of the preceding claims~~according to claim 1, characterized in that it is capable of ~~increases~~increasing the expression of the activation marker CD86 on human B lymphocytes.
14. (Amended) The oligonucleotide as ~~claimed in one of the preceding claims~~according to claim 1, characterized in that it is capable of ~~increases~~increasing the expression of the cytokine receptor CD25 on human B lymphocytes.
15. ~~The use of an oligonucleotide as claimed in one of the preceding claims, for manufacturing a medicinal product.~~
16. ~~The use of an oligonucleotide as claimed in one of claims 1 to 10, for manufacturing a human immunostimulant.~~
17. ~~The use of an oligonucleotide as claimed in one of claims 1 to 10, for manufacturing an immunization adjuvant.~~
18. ~~The use of an oligonucleotide as claimed in one of claims 1 to 10, for manufacturing an immunization composition.~~

20221059203650

19. (Amended) An immunization composition for human use, comprising at least one immunization antigen, ~~characterized in that it also~~ and comprises at least one oligonucleotide as claimed in ~~one of claims 1-10~~ claim 1.
20. (New) A method of stimulating an immune response in a human, the method comprising administering to the human an immunostimulating amount of a composition according to claim 1.
21. (New) A method of enhancing a human immune response to an antigen, the method comprising administering an oligonucleotide according to claim 1 to a human carrying the antigen or administering the oligonucleotide before or with administration of the antigen.

20220519202660

U.S. NAT'L PHASE OF PCT/FR00/01566

New and Clean Version of Amended Claims

1. (Amended) An immunostimulant oligonucleotide comprising at least one nucleotide sequence having the formula 5' TTN₁N₂TT 3', wherein T signifies thymine, and N₁ and N₂ are each independently represent adenine, thymine, cytosine or guanine, and wherein the oligonucleotide lacks a dinucleotide CG in which the cytosine C is not methylated.
2. (Amended) The oligonucleotide as claimed in claim 1 comprising from 6 to 100 nucleotides.
3. (Amended) The oligonucleotide as claimed in claim 1 wherein N₁ represents adenine and N₂ represents guanine.
4. (Amended) The oligonucleotide as claimed in claim 1, wherein the 5' TTN₁N₂TT 3' unit is repeated at least once.
5. (Amended) The oligonucleotide as claimed in claim 4, wherein the 5' TTN₁N₂TT 3' unit is repeated twice.
6. (Amended) The oligonucleotide as claimed in either of claims 4 or 5, wherein the repeated 5' TTN₁N₂TT 3' units are separated by a nucleotide N₃ which is identical or different from other N₃ nucleotides and which is A, C, T, or G.
7. (Amended) The oligonucleotide as claimed in claim 6, wherein the 5'-most nucleotide N₃ is cytosine.
8. (Amended) The oligonucleotide according to claim 1 comprising the sequence 5' TTAGTTCTTAGTTN₃TTAGTT 3', wherein A represents adenine, T represents thymine, G represents guanine and C represents cytosine, and wherein N₃ is A, T, C, or G.
9. (Amended) The oligonucleotide according to claim 1 that induces human lymphocyte proliferation.
10. (Amended) The oligonucleotide according to claim 1 that induces cytokine secretion.

202205203660

11. (Amended) The oligonucleotide as claimed in claim 10 that induces IL 10 secretion.
12. (Amended) The oligonucleotide as claimed in claim 10 that induces γ interferon secretion.
13. (Amended) The oligonucleotide according to claim 1 that increases the expression of the activation marker CD86 on human B lymphocytes.
14. (Amended) The oligonucleotide according to claim 1 that increases the expression of the cytokine receptor CD25 on human B lymphocytes.

19. (Amended) An immunization composition for human use, comprising at least one immunization antigen and at least one oligonucleotide as claimed in claim 1.
20. (New) A method of stimulating an immune response in a human, the method comprising administering to the human an immunostimulating amount of a composition according to claim 1.
21. (New) A method of enhancing a human immune response to an antigen, the method comprising administering an oligonucleotide according to claim 1 to a human carrying the antigen or administering the oligonucleotide before or with administration of the antigen.

20220505 032202